Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs. Ysios Capital was founded in 2008 and has over $450 million in assets under management through its three funds.

Ysios BioFund I 65M EUR (2008)

Ysios BioFund II Innvierte 126,4M EUR (2016)

Ysios BioFund III – 216M EUR (2020)

  • Area of Activity
  • Venture capital
  • Venture capital management company
  • Company type
  • Investors - Venture Capital
Travessera de Gracia, 11 8 pl
Barcelona, Barcelona 08021 , ES
P: +34 93 517 35 45
Avenida de la Libertad, 25, Planta 4
Donostia – San Sebastián , Guipúzcoa 20004, ES
P: 943 108 219

The scientific, financial and entrepreneurial expertise of our international team has proven instrumental to the development of many thriving biotech ventures.

Joël Jean-Mairet, Managing Partner

Júlia Salaverria, Managing Partner

Karen Wagner, Managing Partner

Cristina Garmendia, General Partner

Paula Olazábal, Partner

Raúl Martín-Ruiz, Partner

Guillem Laporta, Partner

Íñigo López-Huerta, CFO

Wen Wen Cheng, Head of Legal

Jordi Xiol, Principal

Thomas Harth, Principal

Salvatore Scaffidi, Investment Analyst

Ysios Capital provides biotech ventures with the resources to develop novel and disruptive therapies for indications with high-unmet medical need, supporting pioneering businesses striving to make a difference in patients' lives.

YBF 3 will invest broadly across multiple therapeutic areas and modalities, targeting seed/early stage and development-stage companies at the forefront of the future of medicine. The total investment size per company will typically be of up to €20 million.

We are deeply rooted within the pharma industry and supported by a first-class network of contacts and advisors.

Equipped with first-hand market insight, we anticipate emerging therapeutic trends and growing areas of interest across a diversity of indications.

We invest in both asset-centric companies and product-enabling platform technologies with a proprietary pipeline. We are agnostic to the therapeutic modality and our investments feature small molecules, antibodies, viruses and living cells.

Ysios Capital